Atara Biotherapeutics
ATRA
118 hedge funds and large institutions have $146M invested in Atara Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 29 closing their positions.
5,919% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $37K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.59% less ownership
Funds ownership: 4.28% → 3.69% (-0.59%)
6% less funds holding
Funds holding: 125 → 118 (-7)
14% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 42
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
51% less capital invested
Capital invested by funds: $298M → $146M (-$152M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.39M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.26M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.59M |
| 4 |
Renaissance Technologies
New York
|
+$1.54M |
| 5 |
BG
Baupost Group
Boston,
Massachusetts
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.9M |
| 2 |
Goldman Sachs
New York
|
-$4.77M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$3.62M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.56M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.53M |
ATRA Hedge Fund Activity: Q2 2023 in Review
118 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2023, worth a combined $146M — down 51% from $298M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ATRA and 22 opened new positions — a net loss of 7 holders — while 42 trimmed existing stakes and 36 added.
The largest buyer was Millennium Management, adding an estimated $2.39M. The largest seller was State Street, cutting an estimated $12.9M.
- 118 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2023, down from 125 in Q1 2023.
- Funds reported $146M of Atara Biotherapeutics stock for Q2 2023, down 51% quarter-over-quarter.
- 22 funds opened new Atara Biotherapeutics positions in Q2 2023 and 29 closed out, a net change of -7 holders.
- The largest Atara Biotherapeutics buyer in Q2 2023 was Millennium Management, an estimated $2.39M added.
- The largest Atara Biotherapeutics seller in Q2 2023 was State Street, an estimated $12.9M sold.
Based on aggregated 13F filings for Q2 2023.